Dynamic SCC-Ag monitoring for predicting recurrence and metastasis in patients with cervical squamous cell carcinoma after definitive concurrent chemoradiotherapy

Objective To investigate the predictive value of dynamic serum squamous cell carcinoma antigen (SCC-Ag) levels and imaging characteristics for recurrence and metastasis in patients with cervical squamous cell carcinoma (CSCC) after definitive chemoradiotherapy. Methods This retrospective study included 215 patients with CSCC who underwent definitive concurrent chemoradiotherapy at the Second Hospital of Dalian Medical University between January 2018 and July 2025. Clinical characteristics, serial SCC-Ag levels, tumor size, and 18F-FDGPET/CT parameters were collected. Logistic regression, Cox regression, and receiver operating characteristic (ROC) curve analyses were performed to identify predictors of recurrence, metastasis, and survival outcomes. Results Post-external beam radiotherapy (EBRT) SCC-Ag level and residual cervical tumor size after EBRT were independent predictors of recurrence and metastasis. SCC-Ag levels at different treatment stages showed different predictive performances, with post-EBRT and end-of-treatment SCC-Ag demonstrating superior predictive ability (AUC=0.66 and 0.68, respectively). An end-of-treatment SCC-Ag cutoff value of 1.33 ng/mL effectively stratified patients with significantly different overall survival and recurrence-free survival. Larger residual tumor size after EBRT was associated with increased recurrence risk (AUC=0.61). PET/CT metabolic parameters showed potential risk stratification value but did not reach statistical significance. Dynamic analysis combining SCC-Ag and imaging findings identified patients with persistent SCC-Ag elevation before radiological recurrence, providing an early warning window. Conclusions Dynamic SCC-Ag monitoring, particularly post-EBRT and end-of-treatment SCC-Ag levels, combined with residual tumor size, may provide valuable prognostic information for recurrence risk stratification and survival prediction in CSCC patients after chemoradiotherapy. Integration of biomarker and imaging-based temporal analysis may facilitate individualized surveillance strategies.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-18
DOI
https://doi.org/10.3389/fmed.2026.2002111
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Dynamic SCC-Ag monitoring for predicting recurrence and metastasis in patients with cervical squamous cell carcinoma after definitive concurrent chemoradiotherapy

Lijuan Zou, Xin Wang, Kun Zou, Yanan Song et al.
Frontiers in Medicine
Endometrial and Cervical Cancer Treatments
article

Dynamic SCC-Ag monitoring for predicting recurrence and metastasis in patients with cervical squamous cell carcinoma after definitive concurrent chemoradiotherapy

Lijuan Zou, Xin Wang, Kun Zou, Yanan Song, Feng Zhang
article en

Abstract

Objective To investigate the predictive value of dynamic serum squamous cell carcinoma antigen (SCC-Ag) levels and imaging characteristics for recurrence and metastasis in patients with cervical squamous cell carcinoma (CSCC) after definitive chemoradiotherapy. Methods This retrospective study included 215 patients with CSCC who underwent definitive concurrent chemoradiotherapy at the Second Hospital of Dalian Medical University between January 2018 and July 2025. Clinical characteristics, serial SCC-Ag levels, tumor size, and 18F-FDGPET/CT parameters were collected. Logistic regression, Cox regression, and receiver operating characteristic (ROC) curve analyses were performed to identify predictors of recurrence, metastasis, and survival outcomes. Results Post-external beam radiotherapy (EBRT) SCC-Ag level and residual cervical tumor size after EBRT were independent predictors of recurrence and metastasis. SCC-Ag levels at different treatment stages showed different predictive performances, with post-EBRT and end-of-treatment SCC-Ag demonstrating superior predictive ability (AUC=0.66 and 0.68, respectively). An end-of-treatment SCC-Ag cutoff value of 1.33 ng/mL effectively stratified patients with significantly different overall survival and recurrence-free survival. Larger residual tumor size after EBRT was associated with increased recurrence risk (AUC=0.61). PET/CT metabolic parameters showed potential risk stratification value but did not reach statistical significance. Dynamic analysis combining SCC-Ag and imaging findings identified patients with persistent SCC-Ag elevation before radiological recurrence, providing an early warning window. Conclusions Dynamic SCC-Ag monitoring, particularly post-EBRT and end-of-treatment SCC-Ag levels, combined with residual tumor size, may provide valuable prognostic information for recurrence risk stratification and survival prediction in CSCC patients after chemoradiotherapy. Integration of biomarker and imaging-based temporal analysis may facilitate individualized surveillance strategies.

Frontiers in MedicineVol. 13
Dalian Medical University (CN), Second Affiliated Hospital of Dalian Medical University (CN), First Affiliated Hospital of Dalian Medical University (CN)
Good health and well-being
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon